-
Science: Break the conventional wisdom!
Time of Update: 2021-08-03
This new study in Lmmermann's laboratory now reveals how neutrophils self-limit their clustering behavior in tissues infected by bacteria, thereby balancing the search phase and the destruction phase to effectively eliminate pathogens .
-
Leukemia: The expression pattern and prognostic potential of circular RNA in mantle cell lymphoma
Time of Update: 2021-08-03
The results of the study revealed that circRNA is a promising potential prognostic biomarker in MCL, and the circSCORE score can improve the identification of high-risk patients .
-
J Clin Oncol: Announcement of the long-term safety and effectiveness of multi-drug chemotherapy for newly diagnosed pediatric T lymphocytic lymphoma (COG AALL0434 study)
Time of Update: 2021-08-03
The COG AALL0434 program evaluated the safety and effectiveness of multi-drug chemotherapy based on Capizzi-based methotrexate/baconase (C-MTX) in patients with newly diagnosed pediatric T-cell lymphoma (T-LL), and obtained Preliminary data on the use of Nelarabine in high-risk patients .
-
J Clin Oncol: Efficacy and toxicity of Pegaspargase and Calaspargase Pegol in the treatment of childhood ALL
Time of Update: 2021-08-03
Childhood Lymphoma ThrombosisThe DFCI 11-001 trial evaluated the efficacy and toxicity of a new type of pegylated asparaginase formulation (Calaspargase Pegol) compared with the standard formulation of Pegaspargase .
After 18 days of induction therapy, 95% or more of the patients in both groups had SAA levels of 0.
-
A landmark achievement in the research of artificial red blood cells in China-"Artificial Universal Blood" is about to enter the phase I clinical research phase
Time of Update: 2021-08-03
In the next 3 to 4 years, this subversive technological achievement of hard science and technology that "changes" animal blood into human blood is expected to be applied to the clinic as a "breakthrough therapeutic drug", effectively solving the shortage of red blood cells of different blood types during clinical treatment, major disasters and wars.
-
Int J Hematol: Romibutine can effectively treat Eltrombopag refractory aplastic anemia
Time of Update: 2021-08-03
, Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study .
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study in this message
-
Blood: Oral ixazomib-lenalidomide-dexamethasone treatment of newly diagnosed multiple myeloma that cannot be transplanted
Time of Update: 2021-08-02
A continuous regimen based on lenalidomide-dexamethasone (Rd) is one of the standard treatments for newly diagnosed multiple myeloma (NDMM) patients who are not eligible for transplantation .
Compared with the placebo-Rd group, the ixazomib-Rd group had a complete response rate (26% vs 14%; odds ratio [OR] 2.
-
NEJM: Darlimumab combination therapy can help improve the prognosis of newly diagnosed AL amyloid patients
Time of Update: 2021-08-02
The darlimumab group has an advantage in survival rate without major organ deterioration or hematological progression (the hazard ratio of major organ deterioration, hematological progression, or death is 0.
-
Concord Kirin mogamulizumab monoclonal antibody submitted a marketing application in China for skin T-cell lymphoma
Time of Update: 2021-08-02
1 months), and the overall response rate increased to 28% (vs 5%)Based on the results of this research, the FDA launched mogamulizumab in August 2018 to treat adult patients with relapsed or refractory mycosis fungoides or Sezari syndrome who have received at least one systemic therapy .
-
Leukemia: Preclinical evaluation of eltrombopag in the PDX model of myelodysplastic syndrome
Time of Update: 2021-08-01
In this study, the researchers aimed to confirm that the previously established MDS PDX model can be used to solve the corresponding clinical problems .
The researchers aim to prove that the previously established MDS PDX model can be used to solve the corresponding clinical problems .
-
Blood: Brentuximab vedotin combined with chemotherapy in the treatment of ALK+ anaplastic large cell lymphoma
Time of Update: 2021-08-01
The Children's Oncology Group (COG) test ANHL12P1 determined the toxicity and efficacy of Bentuximab combined with chemotherapy in newly diagnosed children with nonlocal anaplastic large cell lymphoma kinase (ALK)+/CD30+ ALCL .
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1 .
-
Crit Care: Monocyte distribution width as an indicator for early diagnosis of sepsis in emergency department
Time of Update: 2021-07-31
Monocyte distribution width (MDW) performance as an early sepsis indicator in the emergency department: comparison with CRP and procalcitonin in a multicenter international European prospective study .
-
The long-term survival rate of recurrent AML in children is still low, but the new therapy brings hope
Time of Update: 2021-07-31
However, there are still about 20-40% of AML recurrence young people, up to 70% of patients can not potent chemotherapy and allogeneic stem cells survived transplantation (allo-SCT) high toxicity of the treatment regimen .
-
Nature: How to break the blood-brain barrier?
Time of Update: 2021-07-31
Nature Structural basis of omega-3 fatty acid transport across the blood–brain barrierThe study describes a molecular mechanism that transports Omega-3 to the brain, which may be the key to unlocking the blood-brain barrier and can help researchers develop neurological disease drugs that can better cross the blood-brain barrier .
-
Am J Emerg Med: Mass blood transfusion program for adult trauma patients
Time of Update: 2021-07-31
Mass transfusion programs (MTPs) have become the standard in trauma centers to quickly provide blood products to bleeding patients .
In short, the current mass blood transfusion program should use three main products in a ratio of 1:1:1 and 1:1:2; plasma, platelets and red blood cells .
-
The 2020 impact factor in the field of hematology announced!
Time of Update: 2021-07-31
In January this year, Clarivate published an article stating that the calculation method of the 2020 impact factor announced on June 30, 2021 has undergone some changes, adopting a "forward-looking Mode" .
The "forward-looking model" mentioned here is to include Early Access's article when calculating the impact factor .
-
Merck's Dolaverin listing is expected to help HIV-infected people cope with dyslipidemia
Time of Update: 2021-07-31
Merck announced on June 11, which served monolithic compound preparation De Sizhuo ® (Duo Lami for tablets, Dora Waring 100mg / lamivudine 300mg / tenofovir disoproxil fumarate ester 300mg, DOR / 3TC
-
JCEM: The correlation between body weight and telomere length is mainly mediated by C-reactive protein
Time of Update: 2021-07-31
Researchers aimed to analyze the direct impact of body mass index (BMI) on leukocyte telomere length (LTL) and its C response The indirect effect of protein (CRP) on LTL is to determine the mediating effect of CRP on the association between BMI-LTL .
Researchers used general mediation models to evaluate the mediating effects of CRP on the association between BMI-LTL .
-
Br J Haematol: New discovery can lift the veil of athletes using blood doping
Time of Update: 2021-07-31
Researchers study nucleic acids in red blood cells, especially RNA .
Increased expression of "miR-720" during red blood cell storageIncreased expression of "miR-720" during red blood cell storageAdding recombinant angiotensin to the stored rbc can further enhance the induction of "miR-720" .
-
"Nature": ctDNA testing helps personalized diagnosis and treatment of bladder cancer
Time of Update: 2021-07-31
CtDNA from solid tumors is released into the bloodCtDNA from solid tumors is released into the bloodAccording to a clinical study conducted by Queen Mary University of London, blood tests related to ctDNA may be able to identify the risk of cancer recurrence and guide the precise treatment of bladder cancer after surgery.
